On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
A new protocol paper in Sensors describes a chatbot that doses walking like a drug for patients in diabetic foot remission.
A cost-effectiveness analysis of the DIAFOS trial shows that in-shoe plantar pressure-guided custom footwear saves over €8,000 per ulcer prevented — and adherent patients push the probability of cost-effectiveness to 94%. The economic case for prevention just got stronger.
Footwear plays a crucial role in the health and well-being of individuals with diabetes, particularly concerning the risk of foot ulceration. A recent systematic review published in Diabetic Medicine by Petra J. Jones, David G. Armstrong, Robert Frykberg, Melanie Davies, and Alex V. Rowlands, delves into this critical issue, examining the link between improperly fitting... Continue Reading →
This from our friend Luigi Uccioli and coworkers Abstract Background: Adequate compliance with wearing therapeutic footwear (TF) to prevent diabetic foot ulcers is known to be low. The primary aim of this study was to identify population awareness about the ulceration and/or recurrence risk according to footwear choice. The secondary aim was to evaluate the compliance... Continue Reading →
More wonderful work from our long-time SALSAmigos from the Complutense in Madrid. Aims to assesses the relationship between the wear and tear of therapeutic footwear (TF) and the risk of recurrence in diabetes remission patients. Methods Remission patients (N=115) participated in this 5-year prospective study in a specialized Diabetic Foot Unit between October 2016 and... Continue Reading →
